| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| William A Hargreaves, P Joseph Gibson, Joseph P Gibso. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS drugs. vol 19. issue 5. 2005-07-27. PMID:15907151. |
risperidone and olanzapine are novel antipsychotic medications that compete as first-line agents in treating patients with schizophrenia. |
2005-07-27 |
2023-08-12 |
Not clear |
| William A Hargreaves, P Joseph Gibson, Joseph P Gibso. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS drugs. vol 19. issue 5. 2005-07-27. PMID:15907151. |
we reviewed both randomised and peer-reviewed non-randomised head-to-head (olanzapine versus risperidone) studies in populations with schizophrenia. |
2005-07-27 |
2023-08-12 |
Not clear |
| William A Hargreaves, P Joseph Gibson, Joseph P Gibso. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS drugs. vol 19. issue 5. 2005-07-27. PMID:15907151. |
risperidone and olanzapine provide control of positive, negative and global symptoms of schizophrenia. |
2005-07-27 |
2023-08-12 |
Not clear |
| William A Hargreaves, P Joseph Gibson, Joseph P Gibso. Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review. CNS drugs. vol 19. issue 5. 2005-07-27. PMID:15907151. |
both experimental and naturalistic studies indicated that the acquisition cost of olanzapine is about 50% greater than for risperidone at dose levels commonly used for the treatment of schizophrenia. |
2005-07-27 |
2023-08-12 |
Not clear |
| Norbert Müller, Martin Strassnig, Markus J Schwarz, Markus Ulmschneider, Michael Riede. COX-2 inhibitors as adjunctive therapy in schizophrenia. Expert opinion on investigational drugs. vol 13. issue 8. 2005-07-20. PMID:15268640. |
a general therapeutic effect of the cox-2 inhibitor celecoxib on symptoms of schizophrenia was observed during a prospective, randomised, double-blind study of celecoxib add-on treatment to the atypical antipsychotic risperidone. |
2005-07-20 |
2023-08-12 |
Not clear |
| M B Jayaram, P Hosall. Risperidone versus olanzapine for schizophrenia. The Cochrane database of systematic reviews. issue 2. 2005-07-19. PMID:15846745. |
risperidone versus olanzapine for schizophrenia. |
2005-07-19 |
2023-08-12 |
Not clear |
| M B Jayaram, P Hosall. Risperidone versus olanzapine for schizophrenia. The Cochrane database of systematic reviews. issue 2. 2005-07-19. PMID:15846745. |
antipsychotic medication is a mainstay of treatment for schizophrenia and risperidone and olanzapine are the most popular treatment choice of the new generation drugs. |
2005-07-19 |
2023-08-12 |
Not clear |
| Yasuhiro Kaneda, Tetsuro Ohmor. Impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation. The international journal of neuropsychopharmacology. vol 6. issue 3. 2005-07-18. PMID:12974991. |
impact of risperidone medication on quality of life and gonadal axis hormones in schizophrenia male patients with acute exacerbation. |
2005-07-18 |
2023-08-12 |
human |
| Aygun Ertugrul, Herbert Y Meltze. Antipsychotic drugs in bipolar disorder. The international journal of neuropsychopharmacology. vol 6. issue 3. 2005-07-18. PMID:12974994. |
a small number of patients with schizophrenia treated with risperidone, olanzapine, or quetiapine experience a first episode of hypomania or mania. |
2005-07-18 |
2023-08-12 |
Not clear |
| Ya-Mei Bai, Shun-Chieh Yu, Jen-Yeu Chen, Chih-Yuan Lin, Pesus Chou, Chao-Cheng Li. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. International clinical psychopharmacology. vol 20. issue 2. 2005-07-13. PMID:15729082. |
the present study investigated the effect of risperidone on pre-existing severe tardive dyskinesia among 40 patients with chronic schizophrenia over 48 weeks. |
2005-07-13 |
2023-08-12 |
Not clear |
| Natalie C Edwards, Marcia F T Rupnow, Chris L Pashos, Marc F Botteman, Ronald J Diamon. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. PharmacoEconomics. vol 23. issue 3. 2005-07-11. PMID:15836010. |
cost-effectiveness model of long-acting risperidone in schizophrenia in the us. |
2005-07-11 |
2023-08-12 |
Not clear |
| Natalie C Edwards, Marcia F T Rupnow, Chris L Pashos, Marc F Botteman, Ronald J Diamon. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. PharmacoEconomics. vol 23. issue 3. 2005-07-11. PMID:15836010. |
the availability of a long-acting injection (lai) formulation of risperidone may increase adherence and improve clinical and economic outcomes for people with schizophrenia. |
2005-07-11 |
2023-08-12 |
Not clear |
| Tony Vangeneugden, Annouschka Laenen, Helena Geys, Didier Renard, Geert Molenbergh. Applying concepts of generalizability theory on clinical trial data to investigate sources of variation and their impact on reliability. Biometrics. vol 61. issue 1. 2005-06-30. PMID:15737106. |
this work shows how full modeling power in mixed models can be used to study generalizability using data from five double-blind randomized clinical trials, comparing the effects of risperidone to conventional antipsychotic agents for the treatment of chronic schizophrenia. |
2005-06-30 |
2023-08-12 |
Not clear |
| Patricia A Russo, Mark W Smith, Madhav Namjosh. Health care costs for schizophrenia patients started on olanzapine versus risperidone. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 62. issue 6. 2005-06-21. PMID:15757882. |
health care costs for schizophrenia patients started on olanzapine versus risperidone. |
2005-06-21 |
2023-08-12 |
Not clear |
| Patricia A Russo, Mark W Smith, Madhav Namjosh. Health care costs for schizophrenia patients started on olanzapine versus risperidone. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 62. issue 6. 2005-06-21. PMID:15757882. |
the change in direct medical costs for schizophrenia patients who were started on olanzapine or risperidone and who were privately insured was studied. |
2005-06-21 |
2023-08-12 |
Not clear |
| Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilo. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological psychiatry. vol 57. issue 6. 2005-06-20. PMID:15780844. |
d-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. |
2005-06-20 |
2023-08-12 |
Not clear |
| Ola Gefvert, Bo Eriksson, Per Persson, Lars Helldin, Annika Björner, Erik Mannaert, Bart Remmerie, Mariëlle Eerdekens, Svante Nyber. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. The international journal of neuropsychopharmacology. vol 8. issue 1. 2005-06-13. PMID:15710053. |
pharmacokinetics and d2 receptor occupancy of long-acting injectable risperidone (risperdal consta) in patients with schizophrenia. |
2005-06-13 |
2023-08-12 |
human |
| Ola Gefvert, Bo Eriksson, Per Persson, Lars Helldin, Annika Björner, Erik Mannaert, Bart Remmerie, Mariëlle Eerdekens, Svante Nyber. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. The international journal of neuropsychopharmacology. vol 8. issue 1. 2005-06-13. PMID:15710053. |
thirteen patients with schizophrenia received injections of 25, 50, or 75 mg of long-acting risperidone every 2 wk. |
2005-06-13 |
2023-08-12 |
human |
| Susan R McGurk, Cameron Carter, Robert Goldman, Michael F Green, Stephen R Marder, Haiyi Xie, Nina R Schooler, John M Kan. The effects of clozapine and risperidone on spatial working memory in schizophrenia. The American journal of psychiatry. vol 162. issue 5. 2005-06-08. PMID:15863811. |
the effects of clozapine and risperidone on spatial working memory in schizophrenia. |
2005-06-08 |
2023-08-12 |
Not clear |
| Susan R McGurk, Cameron Carter, Robert Goldman, Michael F Green, Stephen R Marder, Haiyi Xie, Nina R Schooler, John M Kan. The effects of clozapine and risperidone on spatial working memory in schizophrenia. The American journal of psychiatry. vol 162. issue 5. 2005-06-08. PMID:15863811. |
the purpose of this investigation was to evaluate the effects of clozapine and risperidone on spatial working memory in patients with schizophrenia. |
2005-06-08 |
2023-08-12 |
Not clear |